Medpace Holdings (MEDP) Cost of Revenue (2015 - 2026)

Medpace Holdings has reported Cost of Revenue for 12 years, with the latest figure at $510.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 34.21% year-over-year to $510.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (up 28.61% YoY), and the FY2025 full-year result was $1.8 billion, up 21.81% from the prior year.
• Cost of Revenue for Q1 2026 stood at $510.3 million, up from $503.1 million in the prior quarter.
• The five-year high for Cost of Revenue was $510.3 million in Q1 2026, with the low at $232.3 million in Q1 2022.
• Historically, Cost of Revenue has averaged $360.1 million across 5 years, with a median of $359.3 million in 2023.
• Annual changes were most pronounced in 2024 — Cost of Revenue declined 0.92% — and 2025, when it jumped 40.43%.
• Medpace Holdings' Cost of Revenue stood at $278.4 million in 2022, then advanced by 29.9% to $361.6 million in 2023, then dropped by 0.92% to $358.3 million in 2024, then jumped by 40.43% to $503.1 million in 2025, then advanced by 1.42% to $510.3 million in 2026.
• The last three Cost of Revenue figures came in at $510.3 million (Q1 2026), $503.1 million (Q4 2025), and $463.0 million (Q3 2025), per Business Quant data.